Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
A Japanese health ministry panel on April 21 gave the thumbs-up for approving a list of new medicines and label expansions including GlaxoSmithKline’s antibody drug conjugate (ADC) belantamab mafodotin and Moderna’s respiratory syncytial virus (RSV) vaccine. Known with the brand…
To read the full story
Related Article
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- New Usages of Anaemetro, Raiatt Now Eligible for Health Coverage
April 23, 2025
- MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
- MSD Files Keytruda for Malignant Pleural Mesothelioma in Japan
July 2, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
REGULATORY
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
- Takaichi Defends Off-Year Drug Price Revisions as DPP Calls for Abolition
October 9, 2026
- Japan Orders Contraindication for Adlumiz-Noxafil Combination
October 9, 2026
- Imcivree, Hibsago Get Chuikyo Nod for Home Self-Injection
October 9, 2026
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…